Skip to content
Multidisciplinary Association for Psychedelic Studies – MAPS

Multidisciplinary Association for Psychedelic Studies - MAPS

  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Policy & Advocacy
    • Health Equity
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in Trial
    • Volunteer
    • Events
    • Resources
  • Store
    • Learning
    • Apparel
    • Accessories
    • Bookshop
    • 7 Principles
Login
  • Donate
0

Newsletter: December 9, 2016

Newsletter cover image

Newsletter cover image

A Tilt Toward Hope

FDA clears the way for Phase 3 trials of MDMA-assisted psychotherapy for PTSD

December 9, 2016

Dear friends and supporters,

This month, I’m especially excited to bring you the latest news from the Multidisciplinary Association for Psychedelic Studies (MAPS).

Heal Trauma

On November 29, 2016, we met with the U.S. Food and Drug Administration (FDA) to plan our upcoming Phase 3 clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). The outcome was as encouraging as we’d hoped: the FDA is ready for MAPS to move forward with the final stage of research necessary to make MDMA-assisted psychotherapy a legal treatment option for PTSD. We expect formal approval of the Phase 3 trials in early 2017, and starting Phase 3 in June 2017.

Right after the meeting, The New York Times announced the outcome, with the wave of international news coverage that followed bringing unprecedented public attention to our work. Mashable reported that “psychedelic therapy is making a comeback”; New York Magazine called it “a tilt toward hope.”

“It changed my life,” explains Ed, a former firefighter and study participant, to the Times. “It allowed me to see my trauma without fear or hesitation and finally process things and move forward.” U.S. Marine veteran C.J. Hardin recalls: “The MDMA sessions showed me a light I could move toward. Now I’m out of the darkness and the world is all around me.”

Also in the December 2016 edition of the MAPS Email Newsletter:

  • The protocol for our upcoming study of the effects of MDMA on startle testing is cleared by the FDA
  • The 13th participant is treated in our ongoing study of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness
  • The MAPS Store Winter Sale continues until January 7 with discounts on books, clothing, and more
  • Tickets for the Sunset Cruise and Psychedelic Comedy Banquet at Psychedelic Science 2017 are selling fast—register before February 15 to save 10% on Early Bird tickets!

Stay connected by following MAPS on Facebook, Twitter, YouTube, reddit, Tumblr, Pinterest, Google+, LinkedIn, and Instagram.

There is a clear path ahead for the prescription approval of MDMA-assisted psychotherapy for PTSD. Over the next four years, funding this research and educating people about its promise will be our greatest challenges—challenges we will meet together.

Always upwards,

Brad Burge signature

Brad Burge
MAPS Director of Communications and Marketing

P.S. Your $50 gift pays for one full dose of pharmaceutical-grade MDMA for Phase 3 clinical trials. Just like MDMA-assisted psychotherapy, a little bit goes a long way: Help make MDMA a medicine.

Contents


Treating PTSD with MDMA-Assisted Therapy

1FDA Agrees to Phase 3 Trials of MDMA-Assisted Therapy for PTSD

2 Startle Testing with MDMA: FDA Clears Study to Proceed

3 Canada: Study Officially Completed

4 Boulder: 21st Participant Completes 12-Month Follow-Up

5 Israel: Two Participants Complete 12-Month Follow-Up

6 Therapist Training Study: 19th Participant Enrolled

MDMA-Assisted Therapy for Anxiety Associated with Life-Threatening Illness

7 Marin: 13th Participant Treated

Ayahuasca Research

8 Survey: Ayahuasca for PTSD

Psychedelic Harm Reduction

9 Zendo Project: Volunteer at Envision Festival in Costa Rica

Support MAPS

10 Donate to Make MDMA a Legal Medicine

11 November Giving Report: Moving Forward to Phase 3

Media

12 The New York Times⁠⁠: FDA Agrees to New Trials for MDMA as Relief for PTSD Patients

13 The Guardian, Rolling Stone, Fox News, and more…

MAPS Store

14 Winter Sale: New Products and Low Prices

Events

15 Psychedelic Science 2017: April 19-24, 2017, Oakland, CA

16 “A Good Trip” Tour with Comedian Shane Mauss: December 8, 2016-February 10, 2017

17 The Adventure of Self-Discovery: A Holotropic Breathwork Experience with Stan Grof and Tav Sparks: January 27-29, 2017, San Francisco, CA

18 Students for Sensible Drug Policy Annual Conference: March 24-26, 2017, Portland, OR

19 Global Psychedelic Dinners

More News

20 MAPS Bulletin Winter 2016 Annual Report

21 Recap: Catharsis on the Mall 2016

22 MAPS Public Benefit Corporation (MPBC) is Hiring

23 MAPS Volunteer Opportunity: SharePoint Developer and Clinical Management System Integrator

top image

On November 30, 2016, The New York Times published a feature article about the outcome of MAPS’ End of Phase 2 Meeting with the FDA.

Treating PTSD with MDMA-Assisted Therapy


FDA Agrees to Phase 3 Trials of MDMA-Assisted Therapy for PTSD

On November 29, 2016, the U.S. Food and Drug Administration (FDA) hosted staff and researchers at MAPS and the MAPS Public Benefit Corporation (MPBC) for a formal End of Phase 2 Meeting to discuss clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). During the 90-minute meeting at the FDA’s White Oak Campus in Silver Spring, Maryland, the FDA stated they are now ready for MAPS to move forward with Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD. The formal approval of the Phase 3 trial protocol is expected by mid-April 2017.

On November 30, 2016, The New York Times published a feature article announcing the outcome of our End of Phase 2 meeting with the FDA. Trial participants Ed Thompson and CJ Hardin spoke with the NYTimes about how MDMA-assisted psychotherapy helped them overcome treatment-resistant PTSD. “It changed my life,” explains Ed. “It allowed me to see my trauma without fear or hesitation and finally process things and move forward.” CJ speaks about the results from his treatment, stating, “The MDMA sessions showed me a light I could move toward. Now I’m out of the darkness and the world is all around me.”

We expect to initiate our first Phase 3 clinical trial in June 2017, which will last 2-3 years and enroll at least 230 participants. We are working with the FDA’s guidance on determining the final form of the Phase 3 trials, including selection of appropriate control group and sample size.

We need to raise approximately $25-30 million (of which we’ve already raised more than $10 million) to complete Phase 3 trials and all associated toxicity and pharmacology studies over the next 5 years. Phase 3 trials are the final stage of research needed before the FDA will decide whether to approve MDMA-assisted psychotherapy as a prescription treatment for PTSD. There is now a clear path ahead to make MDMA a legal medicine for millions of people suffering from PTSD. Learn more…

Startle Testing with MDMA: FDA Clears Study to Proceed

On November 30, 2016, the FDA cleared the upcoming MAPS-sponsored Phase 1 study on the effect of MDMA on startle testing in healthy volunteers. Principal Investigator Barbara Rothbaum, Ph.D., a leading PTSD researcher, will conduct the study at Emory University in Atlanta, Georgia. The original protocol was approved by the Institutional Review Board (IRB) on July 26, 2016. The DEA is currently reviewing the protocol, with the study expected to begin in 2017. Learn more…

Canada: Study Officially Completed

On November 27, 2016, investigators gathered for the formal closeout of our Phase 2 pilot study of MDMA-assisted psychotherapy for PTSD in Vancouver, Canada. Conducted by Clinical Trial Leader Alli Feduccia, Ph.D., the closeout included a thorough review of the study’s documentation, database, files, and adherence to regulations. All treatment sessions and long-term follow-up interviews for this study have now been completed. Led by Principal Investigator Ingrid Pacey, M.D., this small pilot study gave Canadian therapists experience delivering MDMA-assisted psychotherapy for PTSD, with data collected from three women and three men. The final results are being prepared for publication as a part of a global meta-analysis of MDMA-assisted psychotherapy results. Learn more…

$479,000estimated study cost $48,000raised$69,000raised by partners $353,000still needed

Donate Now

help fund more research

Boulder: 21st Participant Completes 12-Month Follow-Up

On November 28, 2016, the 21st participant out of 23 completed their 12-month follow-up interview in our Phase 2 study of MDMA-assisted psychotherapy in 23 subjects with chronic PTSD in Boulder, Colorado, led by Principal Investigator Marcela Ot’alora, M.A., L.P.C. These data will provide additional information to guide the design of our upcoming Phase 3 trials. The final results are being prepared for publication, which is expected in 2017. Learn more…

$802,000estimated study cost $802,000raised Funding
Complete

Donate Now

help fund more research

Israel: Two Participants Complete 12-Month Follow-Up

On November 10 and November 28, 2016, the fifth and sixth of 10 participants completed their 12-month follow-up interviews in our Israeli Phase 2 study of MDMA-assisted psychotherapy for PTSD. Led by Principal Investigator Moshe Kotler, M.D., this Phase 2 study has treated 10 subjects with chronic, treatment-resistant PTSD from any cause. Learn more…

$509,000estimated study cost $509,000raised Funding
Complete

Donate Now

help fund more research

Therapist Training Study: 19th Participant Enrolled

On November 30, 2016, the fourth participant was enrolled at the recently initiated Boulder, Colorado study site in our ongoing Phase 1 study of the psychological effects of MDMA when used in a therapeutic setting by healthy volunteers. Marcela Ot’alora, M.A., L.P.C., is serving as Principal Investigator of the Boulder site. Enrollment in this study is limited by invitation only to therapists in training to work on MAPS-sponsored clinical trials of MDMA-assisted psychotherapy for PTSD. This study has currently enrolled 19 out of 100
participants across the study sites in Boulder, Colorado, and Charleston, South Carolina. Learn more…

$429,000estimated study cost $35,000raised $394,000still needed

Donate Now

help fund more research

MDMA-Assisted Therapy for Anxiety Associated with Life-Threatening Illness


Marin: 13th Participant Treated

On On November 17, 2016, the 13th participant was treated in our ongoing study of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness in Marin, Calif. Led by Principal Investigator Phil Wolfson, M.D., with Co-therapist Julane Andries, L.M.F.T., this study is gathering preliminary data about the safety and efficacy of MDMA-assisted psychotherapy for anxiety in 18 subjects diagnosed with a life-threatening illness. We are currently screening additional participants for this study. Learn more…

$627,000estimated study cost $218,000raised $409,000still needed

Donate Now

help fund more research

Ayahuasca Research


Survey: Ayahuasca for PTSD

As of December 1, 2016, we have received 202 completed responses for our new anonymous questionnaire about the potential risks and benefits associated with taking ayahuasca as a therapy for posttraumatic stress disorder (PTSD). The data collection is being sponsored by MAPS, with Jessica Nielson, Ph.D., as the Principal Investigator for this study. “Results show a promising trend towards self-reported reductions in PTSD symptoms, depression, and suicidal thoughts and decreased alcohol and prescription drug use, with increases in the use of other psychedelics and MDMA after trying ayahuasca,” explains Nielson. “There are a few reports of the ayahuasca experience itself being traumatizing when done in settings without an experienced facilitator or appropriate after-care.” Take the survey…

Learn more about current and upcoming research at maps.org.

Psychedelic Harm Reduction


Zendo Project: Fundraising Success, Event Updates, and More

zendo-sticker

For the fifth consecutive year, the Zendo Project will provide psychedelic harm reduction services at Envision Festival in Costa Rica, an event taking place in February 2017. Last year at Envision Festival, Zendo Project volunteers provided compassionate support for 116 guests, and dozens more used the Zendo Project facilities as a space to rest and/or rehydrate. Volunteer applications for this event are being accepted until December 12, 2016 Apply to volunteer…

zendo-envision

Zendo Project volunteers at Envision Festival in Costa Rica

Learn about psychedelic harm reduction by signing up for the Zendo Project Email Newsletter, and following the Zendo Project on Facebook, Twitter, and Instagram

MAPS Founder Rick Doblin, Ph.D., and Asana Co-Founder Justin Rosenstein at a fundraising event in San Francisco, California, on December 3, 2016.


Support MAPS


Donate to Make MDMA a Legal Medicine

You can help heal people suffering from PTSD by making a gift toward the production of MDMA needed for U.S. Food and Drug Administration (FDA) Phase 3 clinical trials of MDMA-assisted psychotherapy. To complete these trials, MAPS needs your help to raise the last $174,000 (now just a bit less than $50,000) of the $400,000 needed for one kilogram of pharmaceutical-grade MDMA, made under current Good Manufacturing Practices (cGMP) in a certified laboratory.

327 donors have already brought us 71% of the way to our goal with less than 23 days left!

Every gift helps make a difference in the lives of people suffering from PTSD. Learn more | Make a gift today…

November Giving Report: Moving Forward to Phase 3

In November 2016, MAPS received $210,000 in new donations and pledges from 465 supporters.

November marked the start of what we anticipate will be our final fundraising campaign to raise the remaining $170,000 of the $400,000 required for the purchase of one kilogram of GMP MDMA to be used in our Phase 3 studies of MDMA-assisted psychotherapy for PTSD. We’ve received three generous matches for this campaign so far: $15,000 from Justin Rosenstein, $30,000 from Britt Selvitelle, and $10,000 from the Sarlo Foundation. We’ve already raised over $124,105, 61% of our $174,000 goal. With the help of generous supporters like you, we hope to reach our goal by December 31, 2016.

“Compassion demands that we not deny medicine to the sick,” explains Rosenstein. “I support psychedelic research in the hopes that it will help bring that compassionate care to those who need it most.”

We extend a special thanks to those who so generously supported MAPS this past month:

General Support

  • Nathan Cummings Foundation ($20,000)
  • Audra Foster ($3,000)
  • Douglas & Christine Gehrman Family Foundation ($1,000)
  • Andrew Ryan ($1,000)
  • Flavio Rump ($1,000)
  • Louis B. Bjostad ($1,000)
  • Sahajia Sarkisian ($1,000)
  • Shaun Sutton ($1,000)

MDMA/PTSD Phase 3 GMP MDMA:

  • Ben Warner ($1,000)
  • Hans Petter Sveen ($1,000)
  • Lucy Khoury ($1,000)

Marijuana for PTSD:

  • Julie Holland ($1,202)

Zendo Project:

  • Naval Ravikant ($1,000)
  • Ben Halper ($1,000)

MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations that aren’t family foundations. Learn how to how to include MAPS in your will or estate plans. Learn more about hosting a Global Psychedelic Dinner to bring your community together in support of psychedelic science and medicine.

maps.org/donate

Media


  • The New York Times: F.D.A. Agrees to New Trials for MDMA as Relief for PTSD Patients

    Dave Philipps | November 30, 2016

    On November 30, 2016, The New York Times announced that the U.S. Food and Drug Administration (FDA) is ready for the Multidisciplinary Association for Psychedelic Studies (MAPS) to move forward with Phase 3 clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). Dave Philipps of The New York Times speaks with trial participants C.J. Hardin and Ed Thompson about how MDMA-assisted psychotherapy helped them overcome treatment-resistant PTSD. “It changed my life,” explains Thompson. “It allowed me to see my trauma without fear or hesitation and finally process things and move forward.” Hardin speaks about the results from his treatment, stating, “The MDMA sessions showed me a light I could move toward. Now I’m out of the darkness and the world is all around me.” Read the article…

    The Guardian, Rolling Stone, Fox News, and more…

    • FEATURED

      PBS Radio

      Using Ecstasy to Treat PTSD: ‘I Felt Like My Soul Snapped Back into Place’

      Caleb Hellerman | December 1, 2016

    • FEATURED

      The Guardian

      MDMA Approved for Final Trials to Treat PTSD Before Possible Legalization

      Olivia Salon | December 1, 2016

    • FEATURED

      Popular Science

      MDMA Could be on the Market Legally by 2021

      Knvul Sheikh | November 30, 2016


    • Red State

      The Cure for PTSD? How a Rave Drug Can Be a Treatment

      Jonathan Lubecky | November 16, 2016


    • Rolling Stone

      How MDMA Treats PTSD: Everything You Need to Know

      Annamarya Scaccia | December 1, 2016


    • Fox News

      Ecstasy Trials Approved by FDA for PTSD Patients

      November 30, 2016


    • CBC Radio

      ‘I Have No Doubt it Saved My Life’: MDMA Drug Helps Former Firefighter with PTSD

      Anna Marie Tremonti | December 5, 2016

    • psychcongress
    • Mashable

      ‘I Saw My Fear’: How Psychedelic Therapy is Making a Comeback

      Maria Gallucci | December 5, 2016

    • artstechnica
    • Pharmacy Times

      Is Ecstasy Becoming a Legitimate Medical Treatment?

      Eric Roath, PharmD | December 6, 2016

    Explore MAPS in the Media for more psychedelic and medical marijuana research news.

    MAPS Store


    Winter Sale: New Products and Low Prices

    The MAPS Store Winter Sale features rare artifacts, signed books, new jewelry, 30-40% off select books, 10% off select MAPS apparel. Get a gift for a friend, expand your psychedelic research library, or acquire a rare historic artifact for your collection.

    Featuring:

    • 30-40% off select books
    • Reduced prices on signed books by Albert Hofmann and Alexander “Sasha” Shulgin, including PiHKAL, TiHKAL, and LSD: My Problem Child
    • Rare signed glass from Sasha Shulgin’s laboratory

    All sales support MAPS’ work to expand the scientific, medical, and spiritual uses of psychedelics and marijuana. Discounts from the Winter Sale will be available until January 7, 2017, while supplies last. Shop now…

    Signed glassware from Sasha Shulgin’s laboratory


    ketamine

    The Ketamine Papers: Science, Therapy, and Transformation

    Events


    Browse our Event Calendar for more upcoming events.

    Psychedelic Science 2017: April 19-24, 2017, Oakland, CA

    ps17

    SAVE 10%—REGISTER BY FEBRUARY 15!

    Join us from April 19-24, 2017, in Oakland, California, for Psychedelic Science 2017, a six-day international gathering featuring three days of Conference programming, three full days of Workshops, a Sunset Cruise on the San Francisco Bay, the world’s first Psychedelic Comedy Banquet, a free and expansive Marketplace of goods and ideas, participant-led Community Sessions, and much more. Scientists, doctors, therapists, students, educators, policymakers, artists, and others from around the world will share recently completed and ongoing research into the risks and benefits of psychedelics and medical marijuana for science, medicine, spirituality, creativity, and more. Psychedelic Science 2017 is the third international Psychedelic Science conference, building on the success of Psychedelic Science in the 21st Century (2010) and Psychedelic Science 2013. Past Psychedelic Science conferences sold out early, so reserve your tickets soon. Register now for a 10% discount…

    Psychedelic Science 2017 is presented by MAPS and The Beckley Foundation

    “A Good Trip” Tour with Comedian Shane Mauss: December 8, 2016-February 10, 2017

    Comedian Shane Mauss hosts a hilarious journey through the stigma, history, laws, and science of psychedelics in his new nationwide tour. Shane will share personal experiences and talk about the effects of psychedelics such as mushrooms, LSD, and DMT. Shane is an advocate for psychedelic studies and rights, and psychedelics are also the source of some of the most hilarious, thought-provoking, and well-received material of his career. MAPS is proud to be an honorary sponsor of “A Good Trip.” Register…

    The Adventure of Self-Discovery: A Holotropic Breathwork Experience with Stan Grof and Tav Sparks: January 27-29, 2017, San Francisco, CA

    Join pioneering psychedelic researcher Stanislav Grof, M.D., Ph.D., and Holotropic Breathwork facilitator Tav Sparks for a Holotropic Breathwork experience in San Francisco, Calif., from January 27-29, 2017. Through simple breathing, along with a specially designed musical journey, and a safe and supportive setting with a trained staff of facilitators, you experience a true non-ordinary state of consciousness, allowing deep self-exploration, personal transformation, and healing. Register…

    Students for Sensible Drug Policy Annual Conference: March 24-26, 2017, Portland, OR

    ssdp

    Hosted by Students for Sensible Drug Policy (SSDP), SSDP2017 will bring more than 400 student members, alumni, and supporters to Portland, Oregon, from March 24-26, 2017, for their annual gathering. The conference will feature educational programming, an awards ceremony, a student congress, networking opportunities, and more. Register…

    Global Psychedelic Dinners

    By hosting your own Global Psychedelic Dinner, you’ll join people around the world in gathering your community, having an open conversation about psychedelics, and raising funds to support MAPS. Host a dinner…

    MAPS Bulletin Winter 2016: Vol. 26 No. 3 Annual Report
    Art by Michael Divine

    More News


    MAPS Bulletin Winter 2016 Annual Report

    The Winter 2016 edition of the MAPS Bulletin is now available online and arrives soon in subscriber mailboxes! In addition to our detailed 2016 Annual Financial Report, this issue includes over a dozen original articles from researchers, advocates, MAPS staff, and others. The triannual MAPS Bulletin is a key part of our work to educate the public and encourage scientific research into the safest and most beneficial ways to use psychedelics and marijuana for science, healing, spirituality, and personal growth. Learn more…

    Recap: Catharsis on the Mall 2016

    catharsis image

    From November 11-13, 2016, starting on Veterans Day and immediately following the U.S. presidential election, more than 2,000 people gathered on the National Mall in Washington, D.C., for the second annual Catharsis on the Mall: A Vigil for Healing, a 48-hour event focusing on healing from trauma. The event featured presentations, visionary art, dancing, conversations, and harm reduction services provided by the Zendo Project. MAPS co-created Catharsis with DC community activists, and serves as its fiscal sponsor. We are looking forward to hosting this event again in 2017. Learn more…

    MAPS Public Benefit Corporation (MPBC) is Hiring

    MAPS Public Benefit Corporation (MPBC), a wholly owned subsidiary of MAPS, is currently hiring a Clinical Operations Associate (COA) to work from our office in Santa Cruz, Calif., and support the MPBC clinical research team. The candidate should be comfortable working in a small but fast paced environment while maintaining a positive outlook and attention to detail. The successful candidate will have strong analytical competencies, as well as knowledge in clinical development. The COA is responsible for supporting the Clinical Teams and Clinical Research Sites interactions with Accounting. Learn more….

    MAPS Volunteer Opportunity: SharePoint Developer and Clinical Management System Integrator

    MAPS is currently seeking a volunteer who has experience with Microsoft SharePoint, program management, process improvement, and operations. Learn more…

Post navigation

Previous Newsletter

Newsletter: November 10, 2016

Next Newsletter

Newsletter: January 2017

Multidisciplinary Association for Psychedelic Studies – MAPS
  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
    • Refunds & Returns
    • FAQs
    • Privacy Policy
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Health Equity
    • Policy & Advocacy
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in a Trial
    • Events
    • Resources

Newsletter Sign Up



  • Facebook
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn
  • Reddit
© 1986 - 2022 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved. Disclaimer | Privacy Policy.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117. All Rights Reserved. Proudly powered by WordPress. Hosted by Pressable